

The typical reactivity of C5aR specific mAbs




Figure 1

2/15

Certain mAbs to C5aR inhibit ligand binding

[125I] C5a Ligand Binding Assay





Figure 2

3/15

**Figure 3**

4/15

Complete inhibition of C5aR transfected chemotaxis by select antibodies




Figure 4

5/15

Complete inhibition of L1.2 C5aR transfectant chemotaxis




Figure 5

6/15




Figure 6

7/15




Figure 7

8/15




Figure 8

9/15




Figure 9a

10/15




Figure 9b

11/15




Figure 10

12/15

Anti-C5aR MAb variable light chain DNA sequences

	10	20	30	40	50
7F3 Vk	GATGTTGTGATGACCCAATCTCCACTCTCCCTGCCTGTCAGTCTGGAAA				
6c12 Vk	GATGTTGTGATGACCCAATTCACCTCTCCCTGCCTGTCAGTCTGGAGA				
12d4 Vk	GATGTTGTGATGACCCAATCCACTCTCCCTGCCTGTCAGTCTGGAGA				

	60	70	80	90	100
7F3 Vk	TCAAGCCTCCATCTCTGAGATCTAGTCAGAGCCTTGTACACAGTAATG				
6c12 Vk	TCAAACCTCCATCTCTGAGATCTAGTCAGAGCCTTATACACAGTAATG				
12d4 Vk	TCAAGCCTCCATCTCTGTAGATCTAGTCAGAGCCTTGTACACAGTAGTG				

	110	120	130	140	150
7F3 Vk	GAAACACCTATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAG				
6c12 Vk	GAAACACCTATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAG				
12d4 Vk	GAAACACCTATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAG				

	160	170	180	190	200
7F3 Vk	CTCCTGATCTACAAAGTTCCAACCGATTTCTGGGTCCCAGACAGGTT				
6c12 Vk	CTCCTGATCTACAAAGTTCCAACCGATTTCTGGGTCCCAGACAGGTT				
12d4 Vk	CTCCTGATCTACAAAGTCTCCAACCGATTTCTGGGTCCCAGACAGGTT				

	210	220	230	240	250
7F3 Vk	CAGTGGCAGTGGATCAGGGACAGATTTCTCACTCAAGATCAGCAGAGTGG				
6c12 Vk	CAGTGGCAGTGGATCAGGGACAGATTTCACTCAAGATCAGCAGAGTGG				
12d4 Vk	CAGTGGCAGTGGATCAGGGACACATTCACACTCAAGATCAGCAGAGTGG				

	260	270	280	290	300
7F3 Vk	AGGCTGAGGATCTGGAGTTATTTCTGCTCTCAAAGTACACTTGTTCCTG				
6c12 Vk	AGGCTGAGGATATGGAGTTATTTCTGCTCTCAAAGTACACATGTTCCTG				
12d4 Vk	AGGCTGAGGATCTGGGAATTATTTCTGCTCTCAAAGTACACTTGTTCCTG				

	310	320	330		
7F3 Vk	CTCACGTTGGTGGCTGGACCAAGCTGGAACTGAAA				
6c12 Vk	CCGACGTTGGTGGAGGGCACCAAGCTGGAAATCAAA				
12d4 Vk	CCGACGTTGGTGGAGGGCACCAAGCTGGAAATCAAA				
	* *****				

Figure 11

13/15

Anti-C5aR MAbs variable heavy chain DNA sequences

	10	20	30	40	50
7F3 Vh	CAGGTTCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCCTC				
6c12 Vh	CAGGTTCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCCTC				
12d4 Vh	CAGGTGCAGCTGAAGGAGTCAGGACCTGGCTGGTGGCGCCCTCACAGAG				
	*****	*****	*****	*****	***
	60	70	80	90	100
7F3 Vh	AGTGAAGATTTCTGCAAGGCTTCTGGCTACGCATTAGTAACCTGGAA				
6c12 Vh	AGTGAAGATTTCTGCAAGGCTTCTGGCTACGCATTAGTAGTCCCTGGAA				
12d4 Vh	CCTGTCCATCACATGCACTGTCTGGGTTCTCATTAACCAGCTATGGTG				
	**	**	*****	* ****	* * * *
	110	120	130	140	150
7F3 Vh	TGAACTGGGTGAAGCAGAGGCCTGGAAAGGGTCTTGAGTGGATTGGACGG				
6c12 Vh	TGAACTGGGTGAAGCAGAGGCCTGGAAAGGGTCTTGAGTGGATTGGACGG				
12d4 Vh	TAGACTGGGTCGCCAGTCTCCAGGAAAGGGTCTGGAGTGGCTGGGAGTA				
	* *****	***	** *****	*****	* ***
	160	170	180	190	200
7F3 Vh	ATTATCTGGAGATGGAGATACTAAGTACAATGGAAAGTTCAAGGGCAA				
6c12 Vh	ATTGATGCTGGAGATGGAGATACTAAATACAATGGAAAGTTCAAGGGCAA				
12d4 Vh	ATATG---GGGTGTTGGAAGCACAAATTATAATTCAAGCTCTCAAATCCAG				
	**	** * *****	* * * * *	*****	**
	210	220	230	240	250
7F3 Vh	GGCCACACTGACTGCAGACAAATCCTCCAGCACAGCCTACATGCAACTCA				
6c12 Vh	GGCCACACTGACTGCAGACAAATCCTCCAGCACAGCCTACATGCAACTCA				
12d4 Vh	ACTGAGCATCAGCAAGGACAACCTCCAAGAGCCAAGTTTCTTAAAAATGA				
	* *	*****	***	* * * * *	* * * *
	260	270	280	290	300
7F3 Vh	GCAGCCTGACATCTGAGGACTCTGCGGTCTATTCTGTGCAAGATTCTA				
6c12 Vh	GCAGCCTGACATCTGAGGACTCTGCGGTCTACTCTGTGCAAGCCTCTC				
12d4 Vh	ACAGTCTGCAAACGTGATGACGCAGCCATGTACTACTGTGCCAGCCACT--				
	***	***	*****	* * * * *	*****
	310	320	330	340	350
7F3 Vh	CTTATTAGTACGGTAACAGCCGTTGACTACTGGGGCCAAGGCACCACTCT				
6c12 Vh	ATTACTACGGTAGTGGGAGCTATGGACTACTGGGGTCAAGGAACCTCAGT				
12d4 Vh	ATGGTTACGGACGGCTGGGT-TTGCTTACTGGGGCCAAGGGACTCTGGT				
	* **	**	* * *	*****	* * *
	360				
7F3 Vh	CACAGTCTCCTCA				
6c12 Vh	CACCGTCTCCTCA				
12d4 Vh	CACTGTCTGTGA				
	***	*****	*		

Figure 12

14/15

Anti-C5aR MAbs variable light chain protein sequences

		FR1	CDR1			FR2
		10	20	30	40	50
7F3 Vk		DVVMTQSPSLPVSLGNQASISC		RSSQSLVHSNGNTYLH		WYLQKPGQSPK
6c12 Vk		DVVMTQIPLSLPVSLGDQTSISC		RSSQSLIHSNGNTYLH		WYLQKPGQSPK
12d4 Vk		DVVMTQTPSLSLPVSLGDQASISC		RSSQSLVHSSGNTYLH		WYLQKPGQSPK
		*****	*****	*****	*****	*****
		CDR2	FR3			CDR3
		60	70	80	90	100
7F3 Vk	LLIY	KVSNRFS	GVPDRFSGSGSGTDFSLKISRVEAEDLGVYFC			SQSTLVP
6c12 Vk	LLIY	KVSNRFS	GVPDRFSGSGSGTDFTLKISRVEAEDMGVYFC			SQSTHVP
12d4 Vk	LLIY	KVSNRFS	GVPDRFSGSGSGTHFTLKISRVEAEDLGIYFC			SQSTLVP
		*****	*****	*****	*****	*****
		FR4				
		110				
7F3 Vk	LT	FGAGTKLELK				
6c12 Vk	PT	FGGGTKLEIK				
12d4 Vk	PT	FGGGTKLEIK				
	*	***	*****	.*		

Figure 13

15/15

Anti-C5aR MAb variable heavy chain protein sequences

	FR1			CDR1			FR2			
	10	20	30	NSWMN	WVKQRPKGKLEWIG	R	40	50		
7F3 Vh	QVOLQSGPELVKPGASVKISCKASGYAFS			R						
6c12 Vh	QVOLQSGPEVVKPGASVKISCKASGYAFS			R						
12d4 Vh	QVQLKESGPGLVAPSQSLSITCTVSGFSLT			SYGVD	WVRQSPGKGLEWLGV					
	*****.**** . * * * . * . * . * * . .			.	***.* *****.***.***					
	CDR2			FR3			CDR3			
	60	70	80	KATLTADKSSTAYMQLSSLTSEDSAVYFCAR		90	100			
7F3 Vh	IYPGDGDTKYNGKFKG	KATLTADKSSTAYMQLSSLTSEDSAVYFCAR					FL			
6c12 Vh	IDAGDGDTKYNGKFKG	KATLTADKSSTAYMQLSSLTSEDSAVYFCAS					LL			
12d4 Vh	IW-GVGSTNYNSALKS	RLSISKDN SKSQVFLKMN SLQTDDAAMYYCAS					HY			
	* * * * * * * * * * * .. * *								
	CDR3			FR4						
	110	120		WGQGTTLT	VSS					
7F3 Vh	LIS TVT AVDY	WGQGTTLT	VSS							
6c12 Vh	ITT VVG AMDY	WGQGTT	VSS							
12d4 Vh	GYD GLG-FAY	WGQGTL	VTVSV							
	*	***** . ***								

Figure 14

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.